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MaBACKGROUND Signiﬁcant tricuspid regurgitation (TR) late after left heart valve procedure is frequent and associated
with increased morbidity. Surgical correction carries a signiﬁcant mortality risk, whereas the impact of TR on survival
in these patients is unclear.
OBJECTIVES This study sought to assess the impact of signiﬁcant TR late after left heart valve procedure.
METHODS A total of 539 consecutive patients with previous left heart valve procedure (time interval from valve
procedure to enrollment 50  30 months) were prospectively followed for 53  15 months.
RESULTS Signiﬁcant TR (deﬁned as moderate or greater severity by echocardiography) was present in 91 (17%) patients
(65% female). Patients with TR presented with more symptoms (New York Heart Association functional class $II 55% vs.
31%), lower glomerular ﬁltration rates (61  19 ml/min vs. 68  18 ml/min), and a higher likelihood of atrial ﬁbrillation
(41% vs. 20%), all statistically signiﬁcant. Right ventricular (RV) systolic function was worse in patients with signiﬁcant
TR (RV fractional area change 43  11% vs. 47  9%, p < 0.001). A total of 117 (22%) patients died during follow-up.
By Kaplan-Meier analysis, overall survival was signiﬁcantly worse in patients with signiﬁcant TR (log-rank p < 0.001).
However, by multivariable Cox analysis, only RV fractional area change, age, left atrial size, diabetes, and previous
coronary artery bypass graft procedure were signiﬁcantly associated with mortality, but not tricuspid regurgitation.
CONCLUSIONS RV dysfunction, but not signiﬁcant TR, is independently associated with survival late after left heart
valve procedure. (J Am Coll Cardiol 2014;64:2633–42) © 2014 by the American College of Cardiology Foundation.A lthough signiﬁcant tricuspid regurgitation(TR) is a common ﬁnding (1), data about itsprognostic relevance remain sparse (2–5).
Mostly “functional” in nature, TR is the consequence
of geometric alterations caused by right ventricular
(RV) dilation, distortion of the subvalvular apparatus,
tricuspid annular dilation, or a combination of these
factors (6). Signiﬁcant (moderate and severe) func-
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AF = atrial ﬁbrillation
CABG = coronary artery
bypass graft
CMR = cardiac magnetic
resonance imaging
GFR = glomerular
ﬁltration rate
HF = heart failure
LV = left ventricle/ventricular
RV = right ventricle/ventricular
TR = tricuspid regurgitation
TV = tricuspid valve
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2634(recurrent) signiﬁcant TR (10,11). This setting,
however, frequently poses a challenge for the
treating physician because the surgical risk in
these patients may be substantial, but the
prognostic impact of TR is not well deﬁned.
Discrepant morbidity and mortality rates
have been reported (12–15). Table 1 summa-
rizes the small number of previous studies on
the impact of TR late after left heart valve
procedure. In addition, no data are available
regarding the beneﬁcial effect of isolated
redo tricuspid valve (TV) procedure in these
patients, whereas the procedure carries a
signiﬁcant operative risk, with 30-day mor-
tality rates between 15% (16) and 19% (17).SEE PAGE 2643To clarify the impact of signiﬁcant TR late after left
heart valve procedure on outcome, we performed the
present prospective long-term observational study.
METHODS
STUDY POPULATION. Between January 2007 and
December 2008, 571 consecutive patients with pre-
vious left heart valve procedure presented to our
outpatient heart valve clinic and agreed to partici-
pate in the present observational study. The left
heart valve procedure had to have occurred at
least 6 months before inclusion. Thirty-two patients
with signiﬁcant TR were excluded from further
analysis because of a pacemaker or an implantable
cardioverter-deﬁbrillator (potentially causing or
aggravating TR). Hence, 539 patients were eligible for
statistical analysis. From study entry, all data were
collected prospectively. Patients who underwent1 Summary of Studies With Data on Prognostic Value of Signi
or, Year (Ref. #) N
Surgery (%)
SigniﬁcantAV MV AVþMV þTV
al., 2008 (14) 335 22 52 26 4.5 27%; follo
al., 2009 (12) 638 34 51 15 — 8%; follow
ster et al.,
(13)
801 — 100 — — 9%; follow
16–192
n, %, or mean  SD.
rtic valve; MV ¼ mitral valve; TR ¼ tricuspid regurgitation; þTV ¼ additionaltricuspid repair during follow-up were not excluded.
According to the study design (noninterventional,
purely observational), written informed consent
was not demanded. The ethics committee of the
Medical University of Vienna approved the study
protocol.
CLINICAL DATA. Baseline assessment at study entry
(as detailed in the preceding text) included medical
history, assessment of current medication, phys-
ical examination, electrocardiogram, blood tests, and
a transthoracic echocardiogram.
The following data were collected:
 Age, sex, body mass index, and body surface area
using the Mosteller formula (18)
 Type and number of previous cardiac procedures
 Additive EuroSCORE (19)
 New York Heart Association functional class
 Presence of comorbidities: coronary artery disease
(coronary artery stenosis of >50% lumen loss or
fractional ﬂow reserve <0.8), previous coronary
artery bypass grafting (CABG), chronic obstructive
pulmonary disease (long-term use of bronchodila-
tors or use of steroids for lung disease), arterial hy-
pertension (blood pressure $140/90 mm Hg at
repeated measurements; or use of antihypertensive
agents), atrial ﬁbrillation (AF) (present on the elec-
trocardiogram at index examination or veriﬁed
episode of AF within the last 6 months), hypercho-
lesterolemia (total serum cholesterol$240 mg/dl or
cholesterol-lowering medication), diabetes (fasting
blood glucose level>126mg/dl or use of antidiabetic
medication), estimated glomerular ﬁltration rate
(GFR) using the simpliﬁed Modiﬁcation of Diet in
Renal Disease formula (20)
 Pacemaker/implantable cardioverter-deﬁbrillatorﬁcant TR After Left-Sided Procedure
TR Late After Surgery Comment
w-up 139  25 months Retrospective study
Poorer event-free survival in patients with
TR by Kaplan-Meier analysis, apparent
only after 10 years of follow-up
No multivariable analysis
-up 101  24 months Retrospective study
Poorer survival in patients with TR
by Kaplan-Meier analysis
No multivariable analysis
-up ranging from
months
Retrospective study
No impact of signiﬁcant TR on overall survival
No multivariable analysis
tricuspid valve.
TABLE 2 Echocardiographic Parameters Used for Grading TR Severity
Mild Moderate Severe
Tricuspid valve Normal Normal or abnormal Abnormal/ﬂail leaﬂet/poor
coaptation
Right ventricular/right
atrial/IVC size
Normal* Normal or dilated Dilated
VC width, mm Not deﬁned Not deﬁned, but <7 >7
PISA radius, mm #5 6–9 >9
Hepatic vein ﬂow Systolic dominance Systolic blunting Systolic reversal
*Unless there are other reasons for right ventricular or right atrial enlargement (e.g., pulmonary hypertension,
pulmonary valve disease). Adapted with permission from Lancellotti et al. (21).
IVC ¼ inferior vena cava; PISA ¼ proximal isovelocity surface area; VC ¼ vena contracta; TR ¼ tricuspid
regurgitation.
TABLE 3 Baseline Patient Characteristics
All Patients
(N ¼ 539)
Nonsigniﬁcant TR
(n ¼ 448, 83%)
Signiﬁcant TR
(n ¼ 91, 17%) p Value*
Age at index date, yrs 69.0  11.9
69.0 (62.0–78.0)
68.8  11.6
69.0 (62.0–78.0)
70.2  13.2
75.0 (63.0–79.0)
0.096
Additive EuroSCORE 8.99  2.33
9.0 (7.0–11.0)
8.81  2.26
9.0 (7.0–10.0)
9.84  2.48
10.0 (8.0–12.0)
<0.001
Female 51 48 65 0.004
BSA, m2 1.88  0.22
1.87 (1.72–2.03)
1.89  0.22
1.88 (1.73–2.05)
1.83  0.24
1.83 (1.67–1.97)
0.017
BMI, kg/m2 26.9  4.5
26.2 (23.8–29.3)
26.9  4.5
26.3 (23.8–29.3)
26.6  4.9
25.9 (23.8–29.0)
0.464
Total number of previous
valve procedures
0.019
1 92 93 86
$2 8 7 14
CAD 28 28 26 0.766
Previous myocardial
infarction
7 8 6 0.519
Previous CABG 15 14 18 0.420
Atrial ﬁbrillation 24 20 41 <0.001
Hypertension 61 59 70 0.051
Diabetes 15 14 20 0.164
Hypercholesterolemia 45 47 36 0.069
COPD 9 8 13 0.122
NYHA $2 34 31 55 <0.001
Leg edema 11 9 21 0.003
Jugular vein distension 8 5 20 <0.001
GFR, ml/min 66.3  18.1
64.7 (55.4–79.0)
67.5  17.7
65.5 (56.3–79.5)
60.8  18.8
58.5 (45.5–76.4)
0.002
ICD/PM 5 6 0 0.014
Values are mean  SD, median (interquartile range), or %. *p values for continuous data derive from the
Wilcoxon rank sum test, and the chi-square test was used for categorical data. Values in bold indicate signiﬁcant
p values.
BMI ¼ body mass index; BSA ¼ body surface area; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary
artery disease; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular ﬁltration rate; ICD ¼
implantable cardioverter-deﬁbrillator; NYHA ¼ New York Heart Association functional class; PM ¼ pacemaker;
TR ¼ tricuspid regurgitation.
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2635ECHOCARDIOGRAPHIC DATA. All transthoracic echo-
cardiography studies were performed by board-
certiﬁed physicians, using high-end scanners such
as the GE Vivid 5 and Vivid 7 (GE Healthcare, Wauwa-
tosa, Wisconsin). The evaluation included M-mode
echocardiography, 2-dimensional echocardiography,
and conventional and color Doppler ultrasonography
according to current recommendations (21–23). Left
ventricular (LV) ejection fraction was assessed with
the biplane Simpson’s method. RV function was
assessed by the percent RV fractional area change,
deﬁned as ðend-diastolic areaend-systolic areaÞend-diastolic area  100, accord-
ing to recent recommendations (24). In addition,
tricuspid annular plane systolic excursion was
measured.
TR was quantiﬁed by an integrated approach
(Table 2). Echocardiographic parameters used for
grading included TV morphology; RV, right atrial,
and inferior vena cava size; vena contracta width;
proximal ﬂow convergence radius; and hepatic
venous ﬂow pattern (21,23,25–27). Moderate and
severe TR were considered “signiﬁcant” TR and
were compared with no and mild TR. The gradua-
tion into nonsigniﬁcant TR and signiﬁcant TR was
chosen to account for inaccuracies as a result of
the semiquantitative assessment of TR by echo-
cardiography and has previously been deemed
reasonable (5,28).
STATISTICAL ANALYSIS. Continuous data are ex-
pressed as mean  SD or as median with corre-
sponding interquartile range. Categorical variables
are presented in percent and/or total numbers.
Differences between 2 groups were analyzed using
the Wilcoxon rank sum test. Chi-square tests
and Fisher exact tests were used for categorical
variables. Kaplan-Meier estimates were used to
calculate 1-, 2-, 3-, 4-, and 5-year survival rates.
Differences between survival curves were ana-
lyzed using a log-rank test. Differences in these
and all other tests were considered signiﬁcant at
p # 0.05.
A multivariable Cox regression was performed to
identify parameters associated with overall mortality.
All baseline variables (Table 3) and echocardiographic
measurements (Table 4) were assessed. Variables
with a signiﬁcant univariate inﬂuence (p < 0.05 in
the univariate Cox regression model) were included
in the multiple regression analysis with backward
selection.
In a previous work (5), a strong interaction of
TR and LV systolic function was found. Therefore,
data were also tested for signiﬁcant interactions with
TR, particularly with respect to LV and RV systolicfunction, kidney function, and systolic pulmonary
artery pressure. Statistical analyses were performed
using SPSS Statistics version 18 (IBM, Armonk,
New York) and SAS release 9.2 (SAS Institute, Cary,
North Carolina).
TABLE 4 Echocardiographic Data
All Patients
(N ¼ 539)
Nonsigniﬁcant TR
(n ¼ 448, 83%)
Signiﬁcant TR
(n ¼ 91, 17%) p Value*
LVEDD, mm 46.6  5.9
46.0 (43.0–50.0)
46.5  5.6
46.0 (43.0–49.0)
47.0  6.9
46.0 (43.0–50.0)
0.569
LVEDD/BSA, mm/m2 25.0  3.4
24.7 (22.8–27.0)
24.8  3.2
24.5 (22.7–26.8)
26.0  4.0
25.9 (23.2–28.4)
0.008
RVEDD, mm 33.7  5.3
34.0 (30.0–37.0)
33.1  4.7
33.0 (30.0–36.0)
36.8  6.4
37.0 (32.8–41.3)
<0.001
RVEDD/BSA, mm/m2 18.1  3.2
17.8 (16.1–20.0)
17.7  2.9
17.6 (15.9–19.3)
20.3  3.6
20.2 (18.0–22.3)
<0.001
LA, mm 59.1  9.3
58.0 (53.0–64.0)
57.7  7.8
57.0 (53.0–63.0)
66.0  12.7
64.0 (58.0–73.0)
<0.001
LA/BSA, mm/m2 31.9  6.0
30.9 (28.0–34.6)
30.9  5.0
30.1 (27.6–33.5)
36.5  7.9
34.6 (32.2–40.9)
<0.001
RA, mm 57.0  8.9
55.0 (51.0–61.0)
55.6  7.3
55.0 (51.0–60.0)
63.8  12.3
60.0 (56.0–71.0)
<0.001
RA/BSA, mm/m2 30.7  5.6
30.0 (26.6–33.5)
29.8  4.8
29.2 (26.3–32.7)
35.2  7.1
33.7 (30.8–39.0)
<0.001
LVEF, % 57.4  7.6
59.0 (52.0–63.0)
57.6  7.5
59.0 (52.0–63.0)
56.3  8.2
56.0 (52.0–63.0)
0.202
LVEF <50% 12 11 15 0.285
TAPSE, mm 16.3  4.8
16.0 (13.0–19.0)
16.6  4.6
16.0 (13.0–19.0)
15.5  5.3
15.0 (11.0–19.3)
0.205
RV FAC, % 46.2  9.9
46.0 (41.0–53.0)
47.1  9.4
48.0 (41.0–54.0)
42.5  10.9
42.0 (32.0–51.0)
<0.001
Peak TR velocity, m/s 2.87  0.42
2.8 (2.6–3.1)
2.78  0.35
2.7 (2.5–3.0)
3.23  0.49
3.2 (2.9–3.5)
<0.001
sPAP, mm Hg 40.3  11.5
38.0 (32.0–46.0)
37.4  8.8
36.0 (31.5–41.0)
51.6  13.8
51.0 (41.0–60.5)
<0.001
Signiﬁcant valve
lesion other
than TR
6 4 19 <0.001
MR 4 2 15
AS 0.4 0.4 0
AR 1.7 1.1 4.4
MS 0.4 0.2 0.2
Values are mean SD, median (interquartile range), or%. *p values for continuous data derive from the Wilcoxon
rank sum test, and the chi-square test was used for categorical data. Values in bold indicate signiﬁcant p values.
AR ¼ aortic regurgitation; AS ¼ aortic stenosis; FAC ¼ fractional area change; LA ¼ left atrial longitudinal
diameter, apical 4-chamber view; LVEDD ¼ left ventricular end-diastolic diameter, apical 4-chamber view; MR ¼
mitral regurgitation; MS ¼ mitral stenosis; RA ¼ right atrial longitudinal diameter, apical 4-chamber view;
RVEDD ¼ right ventricular end-diastolic diameter, apical 4-chamber view; sPAP ¼ systolic pulmonary artery
pressure; TAPSE ¼ tricuspid annular plane systolic excursion; other abbreviations as in Tables 2 and 3.
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2636RESULTS
CLINICAL AND SURGICAL DATA. Figure 1 depicts
patient baseline characteristics according to type of
valve procedure. The mean period from left heart
valve procedure to enrollment was 50  30 months.
The majority of patients underwent previous aortic
valve replacement (65%). The remaining patients had
previous isolated mitral valve procedure (19%), com-
bined aortic and mitral valve procedure (10%), or
previous TV surgery in addition to any other valve
(6%). Signiﬁcant TR most frequently occurred in pa-
tients with previous surgery of the TV (34%), followed
by previous combined aortic and mitral valve proce-
dure (25%) and mitral valve procedure alone (17%).In patients with previous aortic valve replacement,
signiﬁcant TR appeared in 14%.
Table 3 shows baseline patient characteristics
according to TR severity. Patients with signiﬁcant
TR were more often female (p ¼ 0.004), had lower
GFR (p ¼ 0.002), more often presented with AF
(p < 0.001), and were more symptomatic (p < 0.001).
They also had more previous valve (redo) procedures
(p ¼ 0.019).
Table 4 displays echocardiographic data at baseline.
TR patients presented with larger left (p ¼ 0.008) and
right (p < 0.001) ventricles, larger left (p < 0.001) and
right (p < 0.001) atria, and worse RV systolic function
(p < 0.001).
Outcome ana lys i s . Patients were followed for 53 
15 months, and all completed follow-up. A total of 117
(22%) patients died during follow-up. Causes of death
are given in Table 5. Cardiovascular death was the
leading cause of mortality and was more frequent
among patients with signiﬁcant TR (p ¼ 0.045). Only
2 patients had TV repair procedure during follow-up:
1 died perioperatively, but the other survived and
remained in the analysis.
By Kaplan-Meier analysis, overall survival was
signiﬁcantly worse in patients with signiﬁcant TR,
with 1-, 3-, and 5-year survival rates of 92%, 81%,
and 64%, respectively, compared with 96%, 89%, and
81% in patients without signiﬁcant TR (log-rank test,
p < 0.001) (Figure 2).
Per the results of the univariable and multivari-
able Cox regression analyses (Table 6), signiﬁcant
TR (p < 0.001), age (p < 0.001), GFR (p < 0.001),
coronary artery disease (p ¼ 0.001), previous CABG
(p < 0.001), New York Heart Association functional
class $2 (p ¼ 0.001), chronic obstructive pulmonary
disease (p ¼ 0.030), diabetes (p ¼ 0.002), left and
right atrial and RV size indexed to body surface
area (all p < 0.001), peak TR velocity (p < 0.001),
and RV systolic function (p < 0.001) were signiﬁ-
cantly associated with survival in the univariable
analysis.
By multivariable analysis, however, only age, left
atrial size, RV systolic function, diabetes, and previ-
ous CABG, but not TR, remained signiﬁcantly associ-
ated with outcome.
We also tested our data for potential interactions,
particularly with respect to LV and RV systolic func-
tion, kidney function, and peak TR velocity. No sig-
niﬁcant interactions were detected.
DISCUSSION
The present prospective, long-term, observational
study of 571 patients examined the impact of
FIGURE 1 Patient Baseline Characteristics According to Type of Valve Surgery
571 patients
Type of previous cardiac procedure
AVR
65%
86%
14% 17%
Non-significant TR Significant TR
25% 34%
83% 75% 66%
MV-procedure
19%
AVR + MV-procedure
10%
TR grade at
index date
Follow-up: 53±15 months
TV + any left-sided procedure
6%
539 patients
50±30 months after left-sided valve procedure
after left-sided valve procedure
32 patients with significant TR and 
PM / ICD excluded
A total of 571 patients were included in the study, of whom 65% underwent AVR, 19% MV procedure, 10% combined AVR and MV procedure,
and 6% TV procedure combined with any left-sided procedure. Pie graphs indicate the percent of signiﬁcant and nonsigniﬁcant TR in the
respective groups. Patients were followed for 53  15 months. AVR ¼ aortic valve replacement; ICD ¼ implantable cardioverter-deﬁbrillator;
MV ¼ mitral valve; PM ¼ pacemaker; TV ¼ tricuspid valve; TR ¼ tricuspid regurgitation.
TABLE 5 Causes of Death
All Patients
(N ¼ 117)
Nonsigniﬁcant TR
(n ¼ 84)
Signiﬁcant TR
(n ¼ 33) p Value
Diseases of the circulatory
system (cardiac death)
68 (58.1) 44 (52.4) 24 (72.7) 0.045
Neoplasms 23 (19.7) 21 (25.0) 2 (6.1) 0.020
Diseases of the respiratory system 9 (7.7) 7 (8.3) 2 (6.1) 1.000*
Endocrine, nutritional and
metabolic diseases
5 (4.3) 5 (6.0) 0 (0) 0.320*
Injury, poisoning, and certain other
consequences of external causes
4 (3.4) 3 (3.6) 1 (3.0) 1.000*
Diseases of the digestive system 3 (2.6) 1 (1.2) 2 (6.1) 0.191*
Diseases of the genitourinary system 2 (1.7) 1 (1.2) 1 (3.0) 0.486*
Symptoms, signs, and abnormal
clinical and laboratory ﬁndings,
not elsewhere classiﬁed
3 (2.6) 2 (2.4) 1 (3.0) 1.000*
Values are n (%). *p values derived from the Fisher exact test; all other p values derived from the chi-square test.
Values in bold indicate signiﬁcant p values.
TR ¼ tricuspid regurgitation.
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2637signiﬁcant TR late after left heart valve procedure. Our
data show that RV dysfunction, but not TR, is inde-
pendently associated with outcome in this setting.
Reoccurrence or new development of signiﬁ-
cant TR late after left heart valve procedure is
found frequently and varies between 9% and 49%
(13–15,29,30). These patients represent a challenging
population because they often experience severe
symptoms, conservative treatment options are lim-
ited, and redo surgery carries a high risk (10,16,17).
Signiﬁcant TR has been identiﬁed as a predictor
of mortality in patients undergoing routine echocar-
diography (4), heart failure (HF) patients (2,3,5) and
patients with mitral valve disease (31–33).
However, for patients presenting with TR late
after left heart valve procedure, the evidence with
respect to the impact of TR on outcome remains
limited. Song et al. (12) retrospectively investigated
more than 600 patients after left heart valve proce-
dure. Late signiﬁcant TR was associated with worse
outcome, deﬁned as a combination of cardiovascular
death, need for redo surgery, and hospital admission
due to congestive HF. Conversely, Garcia Fuster et al.
(13) reported higher frequencies of chronic HF in801 patients with late signiﬁcant TR after left heart
valve procedure, but no signiﬁcant increase in mor-
tality. Kwak et al. (14) retrospectively evaluated
335 patients after left heart valve procedure. The
endpoint, deﬁned as cardiovascular death and redo
CENTRAL ILLUSTRATION Pathogenetic Processes Underlying TR in Patients With Previous Left Heart Valve Procedure
Kammerlander, A.A. et al. J Am Coll Cardiol. 2014; 64(24):2633–42.
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FIGURE 2 Kaplan-Meier Estimate for Overall Survival
Death (n)
Number at Risk
Survival (%)
Failure (%)
Death (n)
Number at Risk
Survival (%)
Failure (%)
Death (n)
Number at Risk
Survival (%)
Failure (%)
Severe TR (n=23)
Moderate TR (n=68)
No/mild TR (n=448)
18
430
96
4
5
63
93
7
2
21
91
9
1
29
419
94
6
8
60
88
12
3
20
87
13
2
50
398
89
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14
54
79
21
3
20
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13
3
69
379
85
15
20
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71
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7
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70
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4
84
364
81
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24
44
65
35
9
14
61
39
5Year
100
80
60
40
20
0
Su
rv
iv
al
 (%
)
0 12 24 36 48 60
Time (Months)
no/mild TR
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severe TR
Numbers at the bottom indicate the number of patients at risk and the number of events
at each follow-up year. A signiﬁcant difference in survival was found between patients
with no/mild TR and moderate TR (log-rank p ¼ 0.001) as well as severe TR (log-rank
p ¼ 0.013). Survival between patients with moderate and severe TR was not different
(log-rank p ¼ 0.762). TR ¼ tricuspid regurgitation.
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2639surgery, was more frequently reached by patients with
signiﬁcant TR, but only after 10 years of follow-up.
It must be emphasized that all these studies
were retrospectively designed and lack assessment of
RV function as well as multivariable regression
analyses.
Therefore, the present large prospective study
adds important information. Our data show that al-
though signiﬁcant TR was strongly associated with
mortality by univariable Cox and Kaplan-Meier anal-
ysis (Figure 2, Table 6), only RV function, but not
TR, remained associated with outcome in the multi-
variable model (Table 6).
Recently, Gulati and coworkers (34) reported on
the important prognostic value of RV function by
cardiac magnetic resonance imaging (CMR) in pa-
tients with dilated cardiomyopathy. RV ejection
fraction of #45% was shown to be signiﬁcantly asso-
ciated with adverse outcome. The present data un-
derline the similar importance of RV function for
prognosis in patients presenting late after left heart
valve procedure. Although assessment of RV function
by echocardiography is challenging, an integrated
approach including assessment of RV size, compre-
hensive visual assessment of contractility, and tri-
cuspid annular plane systolic excursion allows the
distinction between normal and abnormal RV func-
tion with good accuracy (24).
The development or progression of “functional”
TR late after left heart valve procedure follows as a
consequence of geometric alterations of the RV. It
has recently been shown in aortic stenosis patients
that after aortic valve replacement, LV hypertrophy
decreases, but the degree of diffuse interstitial
myocardial ﬁbrosis remains unchanged (35). Diffuse
myocardial ﬁbrosis has been linked with diastolic
dysfunction and elevated LV end-diastolic pres-
sures, promoting post-capillary pulmonary hyper-
tension (36). The elevation of pulmonary pressure
induces RV pressure overload, RV dilation, distor-
tion of the tricuspid valvular apparatus, and ﬁnally,(A) Left heart valve disease causes a rise in left atrial (LA) pressure and in pulmonary arterial wedge pressure, dilating the left atrium. (B) Over
time, LA pressure and pulmonary arterial wedge pressure increase further. Pulmonary vascular compliance declines, adding to the increasing
resistance against the right ventricle (RV). RV end-diastolic pressure rises, leading to right atrial (RA) dilation. Two additional mechanisms may
aggravate RV pressure overload: 1) diffuse ﬁbrosis/extracellular matrix expansion of the left ventricular myocardium (particularly in patients
with aortic stenosis), leading to a further increase in left ventricular end-diastolic and, consequently, LA pressure; and 2) remodeling of the
pulmonary vascular bed. (C) The RV fails to compensate for pressure overload and dilates. Tricuspid annular dilation and distortion of the
subvalvular apparatus lead to increasing tricuspid regurgitation (TR) and subsequent further RA dilation. (D) In many patients, surgical
correction of the left-sided valve lesion does not result in complete regression of the described changes. Postcapillary pulmonary hypertension
persists and may lead to increasing RV size, worsening RV function, and, consequently, increasing TR. The degree of pathological changes
depends on the severity of left heart valve disease and the timing of surgery. LV ¼ left ventricle.
CENTRAL ILLUSTRATION
TABLE 6 Univariable and Multivariable Cox Regression Analysis for All-Cause Mortality
Univariable Cox Regression Analysis Multivariable Cox Regression Analysis
Variable Hazard Ratio (95% CI) p Value* Variable Hazard Ratio (95% CI) p Value*
Age 1.082 (1.060–1.105) <0.001 Age 1.053 (1.022–1.085) 0.001
GFR 0.976 (0.966–0.986) <0.001 LA/BSA 1.044 (1.012–1.077) 0.007
CAD 1.844 (1.272–2.673) 0.001 RV FAC 0.945 (0.922–0.968) <0.001
CABG 2.187 (1.437–3.328) <0.001 CABG 2.469 (1.356–4.496) 0.003
NYHA $2 1.813 (1.257–2.673) 0.001 Diabetes 2.018 (1.084–3.756) 0.027
COPD 1.793 (1.058–3.039) 0.030
Diabetes 1.958 (1.281–2.995) 0.002
Signiﬁcant TR 2.143 (1.432–3.206) <0.001
LA/BSA 1.062 (1.043–1.081) <0.001
RA/BSA 1.067 (1.042–1.093) <0.001
RVEDD/BSA 1.088 (1.038–1.140) <0.001
Peak TR velocity 3.437 (2.349–5.030) <0.001
RV FAC 0.931 (0.910–0.952) <0.001
*p values derive from univariable (left columns) and multivariable (right columns) Cox regression using a backward selection. Values in bold indicate signiﬁcant p values.
CI ¼ conﬁdence interval; other abbreviations as in Tables 2, 3, and 4.
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2640signiﬁcant TR. The assumption that TR late after left
heart valve procedure develops secondary to post-
capillary pulmonary hypertension is supported by
more prominent left atrial dilation in patients with
severe TR, and also higher estimated pulmonary
artery pressures by echocardiography (Table 4). The
Central Illustration displays the pathogenetic pro-
cesses underlying TR late after left heart valve
procedure.
Pulmonary hypertension as a result of left heart
disease (Dana Point 2) can cause signiﬁcant TR,
but correcting TR may not be sufﬁcient to modify
the outcome of these patients. Because of this, RV
function seems to be a more important predictor of
outcome. However, from the pathophysiological
point of view, a double load on the RV (pressure plus
volume related to the presence of TR) will produce
consequences. The presence of signiﬁcant TR leads
to more dilation and more RV systolic dysfunction,
and through this, to worse outcome. However, when
we excluded patients with dilated right heart cham-
bers from the multivariable Cox regression analysis,
similar results were obtained.
The guidelines on the management of valvular
heart disease currently recommend surgical correc-
tion of severe primary TR and of signiﬁcant TR at the
time of left heart valve procedure (10). In patients
who present with TR after previous left heart valve
procedure, the guidelines propose a Class IIa, Level of
Evidence: C recommendation for surgical correction.
The present data challenge this recommendation
because they imply that TR in these patients is a
result of elevated pulmonary pressures, which cannot
be modiﬁed by TV procedure.STUDY LIMITATIONS. We collected the presented
data in a single-center setting; therefore, a center-
speciﬁc bias cannot be excluded. However, the major
advantages of limiting data collection to a single cen-
ter are: 1) inclusion of a homogenous patient popula-
tion; 2) adherence to a constant clinical routine;
3) constant quality of echocardiographic work-up; and
4) constant follow-up.
Renal impairment is a common ﬁnding in patients
with severe TR and RV dysfunction. The majority of
our patients presented with renal dysfunction
(GFR ¼ 66.3  18.1 ml/min) (Table 3). However, in
only 1.9% of patients was GFR <30 ml/min. Thus, our
data are not necessarily transposable to patients with
severe renal failure. The present study is also limited
by the lack of data on rehospitalization for HF. LV
volumes and conduction abnormalities were not
evaluated.
Accurate determination of RV dysfunction in the
presence of signiﬁcant TR is difﬁcult because RV
unloading as a result of TR may be misleading, on top
of technical limitations of 2-dimensional echocardi-
ography used to assess the RV. CMR is currently the
gold standard for the assessment of RV function.
Unfortunately, systematic CMR data are not available
for the present population.
As impairment of RV function in our patients
seems to be linked with elevated pulmonary artery
pressures, caused by high LV ﬁlling pressures,
invasive hemodynamic data would be of great
interest. Unfortunately, systematic right heart cath-
eterization was not performed; thus, hemodynamic
data are only available in a small proportion of our
patients.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Tricuspid regur-
gitation frequently develops late after left heart valve surgery.
However, in contrast to right ventricular dysfunction, age, left
atrial size, diabetes, and previous coronary artery bypass proce-
dure, it is not independently associated with reduced survival.
COMPETENCY IN PATIENT CARE: Isolated surgical correc-
tion of signiﬁcant tricuspid regurgitation may not be beneﬁcial
late after left heart valve procedure.
TRANSLATIONAL OUTLOOK: Further studies are needed to
deﬁne speciﬁc groups of patients who would beneﬁt from isolated
repair of tricuspid regurgitation late after left heart valve procedure.
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2641CONCLUSIONS
Signiﬁcant TR late after left heart valve procedure
is frequent but, in contrast to RV dysfunction, age,
left atrial size, diabetes, and previous CABG, not
independently associated with survival.
In light of these results, isolated surgical correction
of signiﬁcant TR late after left heart valve procedure
may not be beneﬁcial. Further studies are needed to
deﬁne speciﬁc groups of patients who would clearly
beneﬁt from such a procedure.
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